Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multi-strain Probiotics to Prevent NEC in Preterm Infants
NCT06810154Phase 3Not yet recruiting
- Sponsor
- University of Calgary
- Start
- Jun 2025
- Primary completion
- May 2027
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Golden Bifid in necrotizing enterocolitis (NEC) (2 arms), sponsored by University of Calgary. Primary endpoint: Incidence of necrotizing enterocolitis. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
Golden Bifid
03
Conditions
necrotizing enterocolitis (NEC)
Beyond the preview
Go deeper on NCT06810154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06810154.